|
EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node-positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration. |
|
|
Consulting or Advisory Role - Seagen |
Research Funding - AstraZeneca (Inst); Eisai (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - DAVA Oncology; Novocure; Varian Medical Systems |
Consulting or Advisory Role - Novocure |
Research Funding - blue earth diagnostics |
Travel, Accommodations, Expenses - Novocure; Varian Medical Systems |
|
|
Research Funding - Cardiff Oncology (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Kanington Management (I) |
Consulting or Advisory Role - Starmap Medicine and Technology |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; incyte; Janssen; Merck; Nucleix; Urogen pharma |
Consulting or Advisory Role - AstraZeneca; Ferring; Merck |
Research Funding - Epizyme; Merck Sharp & Dohme |
Patents, Royalties, Other Intellectual Property - NMIBC genetic classifier (Inst); TCGA Classifier (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Merck Sharp & Dohme |
|
|
Employment - Oregon Health & Science University (OHSU) |
Honoraria - AstraZeneca; Novocure; UpToDate |
Consulting or Advisory Role - Teladoc |
Research Funding - Novocure (Inst) |
Patents, Royalties, Other Intellectual Property - UpToDate, Inc. chapter royalty |
Travel, Accommodations, Expenses - AstraZeneca; Novocure |
|
|
|
Speakers' Bureau - Accuray |
Research Funding - Accuray |
|
|
Consulting or Advisory Role - GenomeDx |
Speakers' Bureau - Astellas Medivation; Janssen; Johnson & Johnson; Pfizer |
|
|
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med |
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Boston Scientific; Merck; Myovant Sciences; Roivant |
|
|
Consulting or Advisory Role - Exelixis; Foundation Medicine; Pfizer; Roche/Genentech |
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); pfizer (Inst) |